Compare Coinbase Global, Inc. (COIN) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Pfizer Inc — how do they compare? Coinbase Global, Inc. trades at $174.78 (market cap $47.08B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 3.4× Coinbase Global, Inc.'s market cap, and Pfizer Inc pays a 6.14% dividend while Coinbase Global, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Pfizer Inc for 158 Days on average.
| COIN | PFE | |
|---|---|---|
Market Cap | $47.08B | $159.59B |
Volume | 7,082,928 | 30,937,010 |
Sector | Financials | Health |
52-Week High | $387.00 | $29.02 |
52-Week Low | $141.09 | $23.67 |
Typical Hold Time | 78 Days | 158 Days |
Enterprise Value | $44.73B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $172.00, down 7.4% over 24 hours, with a bearish technical signal and recent earnings misses. The company reported $7.18B revenue and $1.26B net income for 2025, but profitability metrics like net income margin and ROE remain negative. Recent news highlights CFTC approval for derivatives expansion and a deepened partnership with Citigroup for stablecoin payments, signaling strategic growth initiatives amid volatile crypto market conditions.
The outlook is mixed: analyst consensus is bullish with a $211.55 price target, but risks include earnings volatility, regulatory scrutiny, and dependence on crypto market cycles. The stock offers growth potential through business diversification, yet investors face significant downside from operational and macroeconomic headwinds.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
